This study investigated the therapeutic effects of a rat glioma cell line, C6, that was engineered to secrete mouse GM-CSF (mGM-CSF) on intracerebral (i.c.) brain tumors. Significant antitumor immunity was induced in rats when the live or irradiated mGM-CSF-secreting tumor vaccine was implanted i.c. The antitumor activity was effective on small tumors and, to a lesser extent, on large tumors or tumors existing in vivo for a longer duration. Immunohistochemical analysis revealed cellular infiltrates (granulocytes, macrophages, and CD4 ϩ and CD8 ϩ T cells) at both the vaccine site and the tumor site, indicating that immune responses were similarly activated when tumor vaccine was inoculated in the brain, as at the subcutis. Additional studies demonstrated that the therapeutic effects of tumor vaccines on the large tumors or the long-existing tumors were enhanced by strategies such as increasing the dosage of tumor vaccines, using combined vaccines consisting of mGM-CSF and human interleukin-2, or combining tumor vaccine with herpes simplex virus thymidine kinase/ganciclovir treatment. All of the modified strategies yielded synergistic therapeutic effects on the large tumor burdens. The data presented herein suggest that cytokine gene therapy is highly promising for the treatment of i.c. gliomas.
M alignant glioma, the most common primary brain tumor, has quite a poor prognosis, even when using multidisciplinary treatment strategies such as surgery, radiotherapy, and chemotherapy. [1] [2] [3] [4] [5] [6] The life expectancy of patients with malignant gliomas is usually Ͻ1 year from the time of diagnosis; the 5-year survival rate is Ͻ5.5%. [1] [2] [3] [4] [5] [6] Therefore, developing a better therapeutic strategy for malignant brain tumors is imperative.
As indicated previously, the central nervous system (CNS) is a barrier to allograft and xenograft rejection, 7, 8 and consequently is considered to be an immunologically privileged site. Antigens (Ags) within the brain do not evoke a response because the brain lacks a lymphatic system, and the blood-brain barrier prevents immune cells from entering the CNS. 7, 8 However, increasing evidence repudiates this concept. Systemic immune responses have been reported in many animal studies involving intracerebrally (i.c.) implanted tumor cells. 9 -11 In addition, Ͼ50% of all malignant gliomas have lymphocyte infiltration (tumor-infiltrating lymphocytes) within and adjacent to tumors, indicating the entry of immune effectors into the brain. [11] [12] [13] [14] Therefore, the brain is now considered to be only a partially immunologically privileged site. 11, 15 If such a case is true, immunomodulation should be able to be used as a therapeutic strategy to enhance the immune response of the brain against malignant tumors.
Recent investigations have tested tumor vaccines that have been genetically engineered to secrete cytokines in terms of their ability to treat tumors implanted in the CNS. 16 -19 However, these studies offered somewhat conflicting results as to the antitumor immunity in the brain induced by cytokine-secreting tumor vaccines. 16 -19 These discrepancies could be due to the different characteristics of tumors; however, the tumor burdens, the types and dosage of cytokines, the duration of tumors existing in vivo, and the administration route of tumor vaccine might also be factors that determine the success of cytokine gene therapy. Our previous data demonstrated the reduction of i.c. tumorigenicity of a C6 glioma model that was genetically engineered to secrete cytokine interleukin-2 (IL-2), IL-4, or GM-CSF. 19 The GM-CSF-secreting tumor cells exhibited a stronger regression effect than the IL-2-or IL-4-secreting tumor cells. 19 Therefore, these results provide preliminary evidence of the induction of antitumor immunity in the brain with the assistance of cytokines.
In this study, we further investigated whether the antitumor immunity elicited by the GM-CSF-secreting tumor vaccine exerted a therapeutic effect on i.c. gliomas. We demonstrated that the antitumor activity did depend upon the cytokine levels, tumor burdens, and patterns of combination treatments. The results presented herein confirm the feasibility of using cytokineassisted tumor vaccine to induce immune responses against malignant tumors in the brain.
MATERIALS AND METHODS

Tissue culture and cell lines
The cell lines used in this study included the GPϩE86 20 and GPϩAM12 21 packaging cell lines and the rat C6 glioma cell line. All cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf sera at 37°C in 5% CO 2 incubator. The C6 glioma cell line is derived from a nitrosomethylurea-induced brain tumor 22 and can rapidly form a nonencapsulated, nonmetastatic tumor after injection into the brain. 23 
DNA construction
A bicistronic retroviral vector, S2, which has been described previously, 24 was used to transduce the genes of interest. cDNA of mouse GM-CSF (mGM-CSF), 25 human IL-2 (hIL-2), 24 or herpes simplex virus thymidine kinase (HSV-tk) 24 was cloned in the multiple cloning region of the S2 vector, yielding the vectors mGM/S2, hIL-2/S2, or TS2, respectively (Fig 1) .
Preparation and infection of recombinant retroviruses
Recombinant retroviruses were produced by transfecting 2 ϫ 10 5 GPϩE86 ecotropic packaging cells with 20 g of plasmid DNA mGM/S2, hIL-2/S2, or TS2, respectively. Viruses were harvested 2 days later and used to infect GPϩAM12 amphotropic packaging cells. Resistant clones were obtained by G418 selection (0.8 mg/mL, Sigma, St. Louis, Mo). The amphotropic virus-producing clones were then expanded and grown until confluence. Next, the filtered culture supernatant from the amphotropic virus producers was used to infect NIH3T3 cells (to determine the titer) or C6 glioma cells in the presence of polybrene (8 g/mL, Sigma). Infected cells were grown in medium containing G418 (0.8 mg/mL) until colonies appeared. The resulting C6 clones bearing the S2 vectors mGM/S2 or hIL-2/S2 were designated as S2/C6, mGM/C6, or hIL-2/C6, respectively. The amphotropic retrovirus-producing cell line bearing the HSV-tk gene was designated as TS2/AM.
Measurement of mGM-CSF and hIL-2 secretion and HSV-tk activity
The secretion of mGM-CSF and hIL-2 was measured in the culture supernatant of transduced C6 cells by enzyme-linked immunosorbent assay (ELISA) (Endogen, Cambridge, Mass). The sensitivity of the TS2-transduced C6 cells to acyclovir was determined in vitro as described previously. 24 A total of 5000 transduced or nontransduced C6 cells were seeded in triplicate wells in increasing concentrations (0, 0.1, 1, 10, 100, and 250 M) of acyclovir for 48 hours in flat-bottom, 96-well microtiter plates. Cell proliferation and viability were subsequently determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide-based colorimetric assay (Boehringer Mannheim, Mannheim, Germany). All procedures were followed according to the manufacturer's instructions.
Animal tumor implantation
Male Wistar rats weighing 200 -350 g were used for animal experiments. The rats were anesthetized with 90 mg/kg ketamine hydrochloride in the following experiments. Tumor implantation was performed by stereotactic surgery. Each rat was fixed in a stereotactic frame, a burr hole was drilled, and tumor cells were injected into the right caudateputamen (CPu) (coordinates: 2.5 mm lateral, 1 mm anterior to the bregma, and 4 mm below the dura) via a Hamilton syringe. Typically, 10 5 -10 6 tumor cells were suspended in a volume of 10 L of phosphate-buffered saline (PBS) solution. The injection was accomplished in 5 minutes, with the syringe remaining in place for 5 minutes; next, the syringe was slowly withdrawn for another 5 minutes.
In vivo treatment experiments
The antitumor effects of the GM-CSF-secreting tumor vaccine were evaluated by three different strategies. First, the effect of the live tumor vaccine was evaluated. Coimplantation of wild-type (wt) C6 and live mGM/C6 tumor vaccine at the same CPu was performed to examine the local paracrine effect; implantations of wt C6 at the right CPu and live mGM/C6 cells in the opposite site were performed to investigate the systemic paracrine effect. Second, the effects of irradiated tumor vaccines were investigated. The wt C6 cells were implanted i.c. The irradiated mGM/C6 tumor vaccines were coimplanted at the right CPu on day 0. A second injection of tumor vaccine inoculated in the opposite site was administered on day 3. This procedure was named the (0,3)-protocol. Alternatively, the irradiated mGM/C6 tumor vaccine was administered at the left CPu on days 7 and 10 after tumor implantation, referred to as the (7,10)-protocol, representing a delayed treatment. Third, the effects of combination therapies on larger tumor burdens (i.e., 1 ϫ 10 6 wt tumor inocula or late-treated tumors derived from 1 ϫ 10 5 C6 cells per inoculation) were studied. The following strategies were used: (a) five times the number of irradiated mGM/C6 tumor cells, (b) combined tumor vaccines consisting of irradiated mGM/C6 cells and irradiated hIL-2/C6 cells, and (c) combination therapies with irradiated mGM/C6 tumor vaccine and HSV-tk/ganciclovir (GCV) treatment. In Figure 1 . Construction of recombinant retroviral vectors. S2 is a modified bicistronic retroviral vector containing multiple cloning sequences (MCS) at the first cistron and a Neo r gene at the second cistron. An internal ribosome entry site (IRES) derived from swine vesicular disease virus (SVDV) was inserted between two cistrons. The gene of interest (mGM-CSF, hIL-2, or HSV-tk) was cloned at the multiple cloning sequences, yielding the construct mGM/S2, hIL-2/ S2, or TS2, respectively. Translation of the first cistron is capdependent, and that of the second cistron is internal ribosome entry site-dependent. Both translations use the same mRNA transcribed from the retroviral long terminal repeat promoter.
the last strategy, the irradiated mGM/C6 tumor vaccine was administered following the (0,3)-or (7,10)-protocol, whereas the HSV-tk producer, TS2/AM, was intratumorally (i.t.) injected on day 3 after wt tumor inoculation. On day 10, GCV at a dose of 15 mg/kg was intraperitoneally (i.p.) injected twice a day for 1 week. The above experiments included control groups that were treated with irradiated C6 or S2/C6. The survival rates of animals from experimental groups and control groups were compared by Fisher's exact test.
Depletion of GM-CSF by anti-GM-CSF antibody (Ab)
In vivo depletion of GM-CSF was performed to determine the cytokine effect. Animals receiving the (0,3)-protocol therapy were treated with five doses of anti-mouse GM-CSF Ab (Endogen), 250 g each. Abs were injected i.p. on days 0, 2, 4, 6, and 8 after an i.c. implantation of wt C6 cells. The survival rates of the animals with or without Ab treatment were observed, and the tumors were examined when the rats died.
Tumor growth, histopathology, and immunohistochemistry
The tumor sizes from both hemispheres, the tumor site, and the vaccine site of the rats treated with live mGM/C6 tumor vaccine on day 1 after an i.c. implantation of wt C6 cells were measured. The rats were sacrificed on days 1 and 3 and on weeks 1, 2, 4, 6, and 9. Their brains were removed and cut along the coronal plane to expose the tumors. The largest diameters of the tumors were measured, and the values of three independent tumors at each timepoint were averaged. The brains were then preserved in 10% formalin for histological examination (hematoxylin and eosin stain) or were embedded in ornithine carbamyl transferase embedding compound (Miles, Elkhart, Ind) and frozen at Ϫ70°C for immunohistochemical examination. For immunohistochemical analysis, 8-m cryostat sections of the brains were prepared. The sections were air-dried at room temperature for 1 hour, fixed in acetone at 4°C for 5 minutes, washed with PBS, and incubated with 0.3% H 2 O 2 (in methanol) for 30 minutes. The sections were then incubated in a blocking solution for 30 minutes. Next, specific Abs were diluted with 1% bovine serum albumin in PBS at an optimal concentration as suggested. Mouse anti-rat CD4 (OX-35), CD8a (OX-8), and macrophage (HIS36) Abs (PharMingen, San Diego, Calif) were used in this study. The Abs were layered onto the section and incubated at 4°C for 12 hours. After two washes with PBS, sections were incubated with a secondary Ab. The sections were washed and processed by the avidin-biotin-peroxidase method. 26 The slides were then counterstained with hematoxylin, mounted, coverslipped, and viewed under a microscope. The spleen was used as a control for the immunohistochemical studies of CD4 and CD8 T cells, and the liver was used for macrophages.
RESULTS
Characterization of cytokine gene-engineered C6 cells and an HSV-tk-containing retrovirus-producing cell line
The cDNA of mGM-CSF, hIL-2, or HSV-tk was cloned in a modified bicistronic retroviral vector, S2, 24 yielding mGM/S2, hIL-2/S2, or TS2 (Fig 1) , respectively. The C6 glioma cells were transduced with recombinant retrovirus containing mGM/S2 or hIL-2/S2; the resulting clones were designated as mGM/C6 or hIL-2/C6, respectively. Secretion of mGM-CSF and hIL-2 from transduced C6 cells was determined by ELISA. According to these results, high levels of both cytokines, 970 ng/10 6 cells/24 hours of mGM-CSF and 120.7 ng/10 6 cells/24 hours of hIL-2, respectively, were produced by C6 cells. Irradiation of the cytokine gene-engineered C6 cells at 4520 rads with a 137 Cs source inhibited cell proliferation, subsequently leading to complete death by day 5. However, cytokine secretion was only insignificantly reduced during the first 4 days, and was completely abolished at day 5 (data not shown). The expression of mGM-CSF in C6 cells did not produce discernible effects on tumor cells, as determined by comparing the growth rates, 19 morphology, and expression of the surface markers (such as major histocompatibility complex (MHC) classes I and II and intercellular adhesion molecule-1 (ICAM-1)) between mGM/C6 cells and parental C6 cells (data not shown).
Amphotropic retrovirus containing HSV-tk gene was generated by transducing TS2-containing ecotropic retrovirus into GPϩAM12 packaging cells. The resulting clone, TS2/AM, had a titer of 9 ϫ 10 5 colony-forming units/mL. The recombinant virus rendered C6 cells sensitive to acyclovir when C6 cells were infected in vitro. 24 Therapeutic effects of live tumor vaccine on i.c. gliomas The retrovirally transduced C6 cells were used as tumor vaccine to examine the antitumor effects on an orthotopic brain tumor model. First, live tumor vaccines were tested. Rats were implanted with wt tumor cells and the tumor vaccines either at the same site or over the contralateral hemispheres. When inoculated at the same CPu, all rats coimplanted with C6 cells and control vaccines, the S2/C6 or C6, died within 34 days after the implantation of tumor cells; all rats coimplanted with C6 and mGM/C6 survived (Fig 2A) . The data suggested that the live GM-CSF-secreting tumor vaccine exerted a local paracrine effect. Similar results were observed when the wt C6 cells and the live tumor vaccines were inoculated in different hemispheres. The rats treated with C6 or S2/C6 on day 1 died, with a mean survival time of 17.2 or 21.3 days, respectively, whereas all of the rats treated with mGM/C6 on day 1 survived (Fig 2B) . Notably, treatment with mGM/C6 on day 3 only rescued 50% (5/10) of the tumor-bearing rats (Fig 2B) . Although the above data suggested that the paracrine effect was systemic, the antitumor activity was more effective when tumors were treated earlier.
Histological and immunohistochemical analyses of the tumor inoculation sites
The histological features were closely examined from rats inoculated with wt tumors and live tumor vaccines in different hemispheres. The tumor sizes were measured over a 9-week observation period in the glioma-bearing rats treated with live mGM/C6 tumor vaccine. As Figure  3 indicates, tumors on both sites grew gradually and reached maximum sizes at week 2 after i.c. implantation, decreasing in size thereafter. At week 2, the tumor sizes at the tumor site (7.7 Ϯ 0.6 mm, mean Ϯ SD) were significantly larger than those at the vaccine site (2.5 Ϯ 2.2 mm) (Student's t test, P Ͻ .01), probably owing to the delayed appearance of immune cells at the tumor site (Table 1) . Few tumor cells remained at the vaccine site at week 6, whereas some tumor cells were still found at the tumor site; however, these cells were completely eradicated at week 9.
Immunohistochemical analyses were performed on both sites of the tumor-bearing animals ( Table 1 and Fig  4) . At the vaccine site, the immune infiltrates closely resembled those described previously, 19 indicating that granulocytes appeared as early as day 1. Infiltration of macrophages, CD4 T cells, and CD8 T cells subsequently followed on day 3. All of the infiltrates were maintained over a 4-week period. By week 6, only residual levels of CD4 T cells and macrophages remained. In contrast to those observed at the vaccine site, cellular infiltrates at the tumor site did not appear until week 1. Macrophages, CD4 T cells, and CD8 T cells were more abundant only until week 2 (Fig 4) . These cells persisted for 2 weeks, and residual levels of macrophages and CD4 T cells were left at week 6. Granulocytes at the tumor site were not detected until weeks 2-4; however, the levels were not as prominent as those at the vaccine site. The above results indicated that the immune cells were indeed activated when the vaccine was implanted i.c., and these immune cells could reach the distal tumor site 4 -6 days later. In the control rats treated with S2/C6 vaccine, no significant levels of Fig 2B) were measured over a 9-week period. Tumors from three rats were measured at each timepoint. Results were shown as mean tumor size Ϯ SD. irradiated tumor cells at the same site on day 0, and vaccine injection was repeated in the opposite site on day 3, namely, the (0,3)-protocol. In the control groups, rats treated with irradiated C6 or S2/C6 cells had only 20% or 27% survival rates, respectively. In contrast, rats treated with irradiated mGM/C6 cells had a 75% survival rate, which was significantly different from the control groups (Fig 5A) .
To confirm that the antitumor immunity was from the action of cytokines rather than the immunogenicity of C6 cells, anti-mouse GM-CSF Ab was used to block the GM-CSF function in vivo. Six rats that received the GM-CSF vaccine were treated with anti-mouse GM-CSF Ab on days 0, 2, 4, 6, and 8 after wt C6 implantation. The data illustrated in Figure 5A show that all six rats that were depleted of GM-CSF by Ab died. This result indicated that the immune reaction induced by irradiated mGM/C6 cells depleted of GM-CSF was too weak to inhibit tumor growth.
The wt tumor inocula were further increased to 1 ϫ 10 6 C6 cells to represent large tumor loads. Rats bearing the large tumor burdens were treated with the same dose of irradiated tumor vaccine following the (0,3)-protocol. The survival rate dramatically decreased to 27%, insignificantly differing from that of the control groups ( Fig  5B) . An alternative large tumor burden was established by inoculating 1 ϫ 10 5 C6 cells at the right CPu; however, the animals were not treated until day 7, intending to mimic better the in vivo microenvironment of a natural tumor. Rats bearing the longer-existing tumors were treated with irradiated tumor vaccine on 0,3) ). Alternatively, rats were inoculated with 1 ϫ 10 5 C6 cells at the right CPu on day 0 and were not treated until day 7, also representing the large tumors. These rats were treated with 1 ϫ 10 6 irradiated mGM/C6 vaccine at the left CPu on days 7 and 10 (mGM/C6(7,10)). The survival rates of the rats were analyzed by Fisher's exact test (P Ͼ 0.1 for mGM/C6(0,3) or mGM/C6 (7, 10) versus S2/C6(0,3) or C6(0,3)). days 7 and 10, designated as the (7,10)-protocol. The survival rate of these rats was 33%, which was similar to that of the rats bearing a large tumor load treated with the (0,3)-protocol (Fig 5B) . These data suggested that the treatment regimen described herein had limited effects on large tumors or tumors existing for a longer duration.
Treatment of large gliomas by various combination strategies Third, we evaluated different combination strategies to enhance the antitumor activity on larger tumors. In the case of 1 ϫ 10 6 wt C6 inocula, three treatment regimens were tested. First, the dose of irradiated tumor vaccine was increased. Animals receiving 1 ϫ 10 6 wt tumor cells were treated with 5 ϫ 10 6 irradiated tumor cells following the (0,3)-protocol. In this study, the 5-fold mGM/C6 vaccine increased the survival rate to 91% (10 of 11 rats); meanwhile, an equivalent dose of S2/C6 control vaccine did not confer any protective effect ( Fig  6A) . Second, a combination of tumor vaccines secreting different cytokines was used. Herein, we combined 1 ϫ 10 6 irradiated mGM/C6 cells with 1 ϫ 10 6 or 3 ϫ 10 6 irradiated hIL-2/C6 cells. According to these results, the addition of 1 ϫ 10 6 hIL-2/C6 increased the survival rate to 64% (7 of 11 rats), whereas the addition of 3 ϫ 10 6 hIL-2/C6 further increased survival to 91% (10 of 11 rats). Both survival rates exceeded those of animals treated with any single type vaccine (40% for 3 ϫ 10 6 hIL-2/C6, and 27% for 1 ϫ 10 6 mGM/C6, respectively) (Fig 6B) . Third, the combination of mGM/C6 tumor vaccine with HSV-tk/GCV treatment was studied. In addition to the (0,3)-treatment protocol with 1 ϫ 10 6 irradiated mGM/C6 cells, the animals were i.t. injected with 1 ϫ 10 6 HSV-tk-containing virus-producing cells, TS2/AM, on day 3. At 1 week after the inoculation of TS2/AM cells, animals received an i.p. injection of GCV for 7 consecutive days. The results summarized in Figure 6C indicate that, whereas any single treatment resulted in partial responses (27% survival rate for 1 ϫ 10 6 mGM/C6 vaccine and 50% for HSV-tk/GCV treatment, respectively), the combined treatment significantly increased the survival rate to 100% (9/9).
For treating 1 ϫ 10 5 tumor inocula that had existed for 1 week, two strategies were evaluated. In the first strategy, animals bearing the large tumors were vaccinated with 1 ϫ 10 6 irradiated mGM/C6 cells plus 3 ϫ 10 6 irradiated IL-2/C6 cells on days 7 and 10 after tumor inoculation. Our results demonstrated that the mixed tumor vaccines yielded a better therapeutic effect (7 of 12 rats, 58% survival rate) than any single type of vaccine (40% for hIL-2/C6 tumor vaccine and 33% for mGM/C6 tumor vaccine, respectively); however, the difference was insignificant (Fisher's exact test, P Ͼ .1) (Fig 7A) . Alternatively, the second strategy, which included mGM/C6 tumor vaccine in conjunction with HSV-tk/ GCV treatment, had more profound antitumor effect. In this strategy, animals inoculated with 1 ϫ 10 5 wt C6 cells at the right CPu were treated with 1 ϫ 10 6 irradiated mGM/C6 tumor vaccine at the left CPu on days 7 and 10. In addition, these animals were injected i.t. with 1 ϫ Figure 6 . Combination therapies on rats inoculated with large tumor loads. Rats bearing the large tumors (1 ϫ 10 6 inocula) were treated with the following modified treatments: A: 5-fold tumor vaccines. A total of 1ϫ or 5ϫ (1ϫ ϭ 1 ϫ 10 6 cells) irradiated tumor vaccines were administered by the (0,3)-protocol. The survival rates of the rats were analyzed by Fisher's exact test (P Ͻ .003 for mGM/C6 (5ϫ) versus mGM/C6 (1ϫ)); (B) Combined tumor vaccines consisting of mGM/C6 and hIL-2. Irradiated mGM/C6 tumor vaccine (1ϫ) plus irradiated hIL-2/C6 tumor vaccine (1ϫ or 3ϫ) were coadministered by the (0,3)-protocol. The survival rates of the rats were analyzed by Fisher's exact test (P Ͻ .004 for mGM/C6 (1ϫ) or hIL-2/C6 (3ϫ) versus mGM/C6 (1ϫ) plus hIL-2/C6 (3ϫ)); C: Tumor vaccine plus HSV-tk/GCV treatment. Rats were treated with 1 ϫ 10 6 irradiated mGM/C6 vaccine by the (0,3)-protocol. In addition, they were injected i.t. with 1 ϫ 10 6 HSV-tk-producing cells, TS2/AM, on day 3. GCV (15 mg/kg, i.p., twice a day) was administered 1 week after TS2/AM inoculation for 7 consecutive days (mGM/C6ϩTS2/ GCV). Either vaccine treatment alone (mGM/C6) or HSV-tk/GCV treatment alone (TS2/GCV) was performed in parallel for comparison. The survival rates of the rats were analyzed by Fisher's exact test (P Ͻ .002 for mGM/C6 versus mGM/C6ϩTS2/GCV; P Ͻ .02 for TS2/GCV versus mGM/C6ϩTS2/GCV).
10
6 TS2/AM cells on day 7; after 1 week, GCV was administered for 7 consecutive days. As a result of this combination treatment, the survival rate was significantly improved (11 of 11 rats, 100%), i.e., much better than any single treatment alone (50% for HSV-tk/GCV treatment and 33% for mGM/C6 treatment, respectively) (Fig 7B) .
The above results demonstrated the synergistic effects among different tumor vaccines or various treatments that might positively influence animals bearing large tumor burdens.
DISCUSSION
The brain has long been considered an immunologically privileged site, because allogenic skin grafts or tumors that were rejected when transplanted subcutaneously would often grow when transplanted in the brain. 7, 11 In addition, tumors established within the CNS have failed to respond to other forms of systemic immunotherapy. [27] [28] [29] [30] The CNS may pose a barrier to using cytokinesecreting tumor vaccine. However, according to recent evidence, the immunity elicited by the subcutaneous injection of cytokine-secreting tumor vaccines can regress tumors implanted in the brain, suggesting that the immunologically privileged CNS is not an absolute barrier to this form of active, specific immunotherapy. 17, 18 Furthermore, our previous study demonstrated that the inoculation of cytokine-secreting tumor cells in the brain could elicit strong immune reactions to inhibit the tumor growth. 19 These data indicate that immune responses are possibly activated in the brain. However, the antitumor immunity does not result from the increase of immunogenicity of tumor cells being engineered with cytokine gene, as the levels of surface markers (MHC classes I and II and ICAM-1 molecules) and the secretion of the transforming growth factor (TGF) of the mGM-CSF-secreting C6 cells were not significantly different from that of parental C6 cells (data not shown). In contrast, the data illustrated in Figure 5A demonstrated that in vivo depletion of the mGM-CSF from the inoculated tumor vaccine led to tumor growth. Taking these results into account, the immune reaction in the brain is most likely induced by the action of cytokines rather than by the immunogenicity of the C6 cells.
In this study, we provided evidence further demonstrating that the immunity induced locally by cytokinesecreting tumor vaccine in the brain exerted paracrine therapeutic effects on the neighboring or distal wt tumors. Histological analyses directly confirmed that immune cells (granulocytes, macrophages, and CD4 and CD8 T cells) appeared rapidly at the vaccine site, probably owing to a local reaction in response to the GM-CSF secretion; in contrast, ϳ4 -6 days are necessary for them to migrate to a distal wt tumor site. Because the brain lacks a lymphatic system, 7,8 the induced immune cells at the vaccine site probably needed to circulate systemically and ultimately reentered the brain and infiltrated into the tumor site. Although it remains unclear as to whether the late appearance of immune effectors at the tumor site is attributed to the blood-brain barrier to systemic immunity, the slower regression of tumors at the tumor site compared with regression at the vaccine site (Fig 3) was consistent with this notion. Taken together, these results were inconsistent with the idea that the brain is immunologically privileged; consequently, these results conferred the possibility of treating malignant brain tumors with cytokine-assisted tumor vaccines.
As another significant contribution, this study provides possible treatment regimens for large tumor burdens or tumors existing for a longer duration. Whereas 6 cells) and hIL-2/C6 vaccine (3ϫ) were coadministered on days 7 and 10 after tumor implantation. The survival rates of the rats were analyzed by Fisher's exact test (P Ͼ .1 for mGM/C6 (1ϫ) or hIL-2/C6 (3ϫ) versus mGM/C6 (1ϫ) plus hIL-2/C6 (3ϫ)). B: Tumor vaccine plus HSV-tk/ GCV treatments. Irradiated mGM/C6 vaccine (1ϫ) was administered by the (7,10)-protocol. In addition, 1 ϫ 10 6 TS2/AM cells were injected i.t. on day 7. GCV was administered as described in the legend to Figure 6C . The survival rates of the rats were analyzed by Fisher's exact test (P Ͻ .002 for mGM/C6 versus mGM/C6ϩTS2/ GCV; P Ͻ .02 for TS2/GCV versus mGM/C6ϩTS2/GCV).
the therapeutic effects of treatment with two doses (1 ϫ 10 6 cells each) of irradiated tumor vaccine were very limited, the effects could be enhanced by several strategies, including increases of vaccine dosage, a combination of tumor vaccines secreting different cytokines, and a combination of tumor vaccine with suicide gene transfer. The notion of increasing tumor vaccine dosage was based on the observation that one dose (1 ϫ 10 5 cells) of live mGM/C6 tumor vaccine yielded better therapeutic effects than two doses (1 ϫ 10 6 cells each) of irradiated mGM/C6 tumor vaccine with regard to treating the same tumor burden (100% vs. 75% survival rate; Figs 2B and 5A, respectively). Because it took ϳ6 weeks for the live mGM/C6 cells to completely disappear from the vaccine site (Fig 3) , secretion of mGM-CSF from the live tumor vaccine would last for the whole time period at least, and would be maintained at higher levels than that from the irradiated tumor vaccine. We thought that higher levels of GM-CSF might recruit more professional Ag-presenting cells (APCs) into the vicinity of tumors, thereby enhancing T-cell activation. The conjecture was confirmed by administering 5-fold tumor vaccines to animals bearing large tumor burdens; indeed, the survival rate was greatly increased (Fig 6A) . Whether the administration of a higher dose of mGM/C6 tumor vaccine would cause devastating effects or induce an abnormal immune response in the animals is unclear and remains to be determined.
Multiple steps and many regulatory cytokines are generally required to reach a maximal immune response in vivo. Consequently, how to deliver the most potent combination of cytokines to achieve the maximal antitumor immunity becomes a critical issue in developing an effective tumor vaccine. In this study, combining GM-CSF-secreting tumor vaccine with IL-2-secreting tumor vaccine yielded synergistic antitumor effects on large tumor burden. In addition, higher dosages of IL-2-secreting tumor vaccine yielded better effects (Fig 6B) . IL-2 is a T-cell growth factor and an important indicator of the magnitude of immune responses. 31 This cytokine has been tested in many tumor vaccines and has been demonstrated to be successful in some tumor models with respect to inducing antitumor immunity. [32] [33] [34] According to previous investigations, a local secretion of IL-2 stimulates the activation and proliferation of the tumor-specific T cells by bypassing T-cell help. 31, 32, 34 As a result, the mechanism for the synergistic effect could be that local GM-CSF secretion enhances inflammation and recruits the APCs that activate the T cells in the vicinity of tumors, whereas locally expressed IL-2 acts synergistically to enhance the proliferation of tumorspecific cytolytic T cells. However, according to our results, a combination of these two tumor vaccines did not markedly improve the survival rate of rats bearing tumors existing for a longer duration (Fig 7A) . It is possible that the tumor burden from this model (i.e., 7 days after 1 ϫ 10 5 inoculation of wt C6 cells) surpasses 1 ϫ 10 6 inoculum, thereby diminishing the effects of combined tumor vaccines. However, it is also possible that an immunologically suppressed status was already established in the animals bearing longer-existing tumors, 25 and that this suppression could not be adequately overcome by immunotherapy. Indeed, the latter possibility very likely exists in animals bearing large tumors, and will pose a challenge to the application of immunotherapy alone.
According to previous data, combining IL-2 with HSV-tk/GCV treatment does not enhance the antitumor effect on an i.c. glioma model compared with treatment with HSV-tk/GCV alone. 16 In contrast, this study demonstrated that combining mGM-CSF tumor vaccine with HSV-tk/GCV treatment profoundly increased antitumor activity. The synergistic effects were observed on tumors derived from large inoculum (Fig 6C) and on tumors present in vivo for a longer duration (Fig 7B) . The discrepancy between these two studies could be attributed to the different functions of these two cytokines. HSV-tk/GCV treatment probably led to tumor cell death, thereby reducing the tumor sizes to a certain extent. Therefore, the simultaneous administration of immunotherapy seemed to function more easily on the reduced tumor burdens. Alternatively, and possibly more importantly, the disruption of cells owing to HSVtk/GCV treatment led to the uptake of tumor-derived Ags by APCs. The primary function of GM-CSF is to recruit more APCs into the vicinity of tumor cells, thereby enhancing Ag presentation and T-cell activation. However, IL-2 does not provide similar functions, nor does it lead to synergistic effects. It remains possible that some other cytokines can also work with HSV-tk/ GCV treatment, subsequently giving rise to synergistic therapeutic effects.
In sum, although immunotherapy using cytokine-assisted tumor vaccine is effective on small tumors, it is probably much more important that such a treatment strategy be used in treating large tumors or tumors present in vivo for a long duration. In the case of malignant i.c. gliomas, surgical operations are generally limited by the infiltrative nature of the tumors and the intention of preserving neurological function; completely excising the whole tumor in clinical conditions is extremely difficult. Under such circumstances, cytokine gene therapy might have an adjuvant function after surgical resection, because cytokine-secreting tumor vaccine can provide systemic and long-lasting effects and eventually eradicate all residual tumor cells and prevent remission. Because a single tumor vaccine may not function adequately on large tumors, combined treatment strategies may provide more significant antitumor effects. In conclusion, we believe that cytokine-assisted gene therapy is highly promising in treating malignant brain tumors. 
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